[ad_1]
(MedPage Today) — The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary endpoint in amyotrophic lateral sclerosis (ALS), but its findings shed light on ALS clinical research…
[ad_2]
Source link : https://www.medpagetoday.com/neurology/generalneurology/114804
Author :
Publish date : 2025-03-24 21:42:00
Copyright for syndicated content belongs to the linked Source.